Merck has decided to return to Scynexis all development and commercialization rights for the novel antifungal compound MK-3118, an oral glucan synthase inhibitor being developed for the treatment of systemic fungal diseases. This decision was made following a review and prioritization of Merck’s infectious disease portfolio.

In 2002, Scynexis and Merck announced an exclusive license and research agreement focused on antifungal discovery and development of treatments for invasive fungal infections such as Candida and Aspergillus. MK-3118 is the first compound developed under the agreement to have completed Phase I studies and be ready to enter Phase IIb studies.

“We have enjoyed a successful collaboration with our Merck colleagues and will continue to advance the clinical development of MK-3118, now SCY-078, to help a growing and under-served patient population,” said Yves Ribeill, Ph.D, president and chief executive officer, Scynexis. “The addition of this anti-fungal platform to our portfolio expands our pipeline and positions Scynexis as a leading anti-infective company.”

“Working together, we have made good progress in advancing MK-3118 to this clinical stage,” said Roger Pomerantz, senior vice president and head, Worldwide Licensing and Knowledge Management, Merck. “Merck continues to advance its infectious disease pipeline and remains committed to delivering medicines in this important therapeutic area.”

Under the terms of the agreement, Scynexis will receive all rights to MK-3118, including a transfer from Merck to Scynexis of the preclinical, IND and Phase I data packages. The company plans to progress the clinical development while simultaneously evaluating new partnership opportunities. Merck will be eligible to receive milestones and royalties.